Doctoral School of Exact and Natural Sciences, University of Lodz, 90-237 Lodz, Poland.
Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, 90-237 Lodz, Poland.
Int J Mol Sci. 2020 Jul 12;21(14):4919. doi: 10.3390/ijms21144919.
Irinotecan has been used in the treatment of various malignancies for many years. Still, the knowledge regarding this drug is expanding. The pharmacogenetics of the drug is the crucial component of response to irinotecan. Furthermore, new formulations of the drug are introduced in order to better deliver the drug and avoid potentially life-threatening side effects. Here, we give a comprehensive overview on irinotecan's molecular mode of action, metabolism, pharmacogenetics, and toxicity. Moreover, this article features clinically used combinations of the drug with other anticancer agents and introduces novel formulations of drugs (e.g., liposomal formulations, dendrimers, and nanoparticles). It also outlines crucial mechanisms of tumor cells' resistance to the active metabolite, ethyl-10-hydroxy-camptothecin (SN-38). We are sure that the article will constitute an important source of information for both new researchers in the field of irinotecan chemotherapy and professionals or clinicians who are interested in the topic.
伊立替康多年来一直用于治疗各种恶性肿瘤。然而,人们对这种药物的了解还在不断扩展。药物的药物遗传学是对伊立替康产生反应的关键组成部分。此外,还引入了该药物的新配方,以便更好地输送药物并避免潜在的危及生命的副作用。在这里,我们全面概述了伊立替康的分子作用模式、代谢、药物遗传学和毒性。此外,本文还介绍了该药物与其他抗癌药物联合使用的临床组合,并介绍了药物的新配方(例如,脂质体配方、树枝状聚合物和纳米颗粒)。它还概述了肿瘤细胞对活性代谢物,依立替康(SN-38)的乙基-10-羟基喜树碱的耐药的关键机制。我们相信,这篇文章将成为伊立替康化疗领域的新研究人员以及对该主题感兴趣的专业人士或临床医生的重要信息来源。